Shire’s $5.2 Billion Gamble Pays Off as NPS Drug Wins Approval

January 24, 2015 12:05 AM

4 0

NPS Pharmaceuticals Inc. (NPSP) won U.S. approval for the first drug to treat a rare hormonal abnormality, vindicating Shire Plc (SHP)’s gamble to buy the company for $5.2 billion before the outcome was publicly known.

The Food and Drug Administration cleared Bedminster, New Jersey-based NPS’s Natpara to control low blood calcium levels related to hypoparathyroidism, according to a statement from the agency. The drug may garner $665 million in sales by 2021, according to Chiara Russo, an analyst at Janney Montgome...

Read more

To category page